Kolon Life Science and TissueGene have laid the foundation for a comeback. This is due to the technology export of Invossa (TG-C), an arthritis treatment that fell to hell because domestic sales were stopped, to a Singaporean pharmaceutical company. As Invossa is re-evaluated in the global market, it is expected that the perspective on ‘failure’ that may occur during the development of a new drug will gradually change.
- Paid Service
-
This article is a paid service and can be used following payment.
Please check the subscription application guide. -
Subscription application and information
login
